Compounds › Metabolic and weight

5-Amino-1MQ

Small molecule, not a peptide, studied in fat and NNMT

Not approvedMetabolic and weight

Experimental material. Read before using anything from here.

Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.

Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.

Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.

Summary

Short for 5-amino-1-methylquinolinium. It is a small molecule, not a true peptide, even though it is sold alongside research peptides. Interest centers on two targets: reducing the size of fat cells and inhibiting the NNMT enzyme. It exists as an oral capsule and in injectable form, and most of what circulates as a protocol comes from community reports, not from clinical trials.

Quick reference

Class: NNMT inhibitor, small molecule. Not a peptide.
Most common route: Oral capsule, 50 to 150 mg per day, in the morning.
Interest: Reduction in fat cell size and increase in NAD+, without appetite suppression.
Status: Not approved by the FDA (July 30, 2026). No published human trial.

5-Amino-1MQ Protocol Formats

Phase	Daily dose	Units on U-100 syringe	Volume
Days 1–2 (tolerance)	2.5 mg 1×/day	15 units	0.15 mL
Days 3+ (standard)	5 mg 1×/day	30 units	0.30 mL
Split option (2×/day)	2.5 mg 2×/day	15 units each	0.15 mL each

Oral dose and evidence

Phase	Daily dose	Notes
Weeks 1–2 (start low)	50 mg 1×/day	Morning dosing is the pattern most often reported; sleep, energy, and digestion changes are commonly monitored in community reports.
Weeks 3+ (standard)	100 mg 1×/day	The most common research community target dose.
Weeks 3+ (higher end)	150 mg 1×/day	Some sources go this high. Diminishing returns and more side effects are reported above 150 mg.
Split option	50 mg morning + 50 mg midday	Some sources prefer split AM dosing because the plasma half-life is short (about 4 to 7 hours in rodent PK).

5-Amino-1MQ Oral Capsules vs Injection

Factor	Oral capsules	Subcutaneous injection
Administration	Capsule taken by mouth	Reconstituted solution placed under the skin
Commonly discussed research amounts	50 to 150 mg per day in community reports	2.5 to 5 mg per day in community reports
Frequency	1×/day or split between morning and midday	Generally discussed as 1×/day, with some examples of split dosing
Absorption evidence	38.4% oral bioavailability in one rat study; human bioavailability is unknown	Human subcutaneous bioavailability and pharmacokinetics are unknown
Convenience	No mixing or syringe math	Requires reconstitution, sterile supplies, and injection-site planning
Evidence limits	No controlled human dose, benefit, or safety trial	No controlled human dose, benefit, or safety trial
Can the amounts be treated as equal?	No. Route changes exposure, and rat data cannot provide a safe conversion.	No. A smaller injected amount is not proven equal to a larger oral amount.

Half-life and dosing frequency

Measure	Published finding	What it means
IV half-life	3.80 ± 1.10 hours in rats	Animal IV data only; it does not describe oral or subcutaneous timing in people.
Oral half-life	6.90 ± 1.20 hours in rats	Animal oral data only; it is not an established human half-life.
Oral bioavailability	38.4% in rats	Shows that some oral absorption occurred in that model. Human absorption may differ.
Subcutaneous half-life	Not established in humans	Skipping the gut may change exposure, but no safe route conversion can be calculated from current data.

5-Amino-1MQ Reconstitution Guide

BAC water added	Final concentration	Research amount	Draw volume	U-100 syringe units
1.0 mL	10 mg/mL	1 mg	0.10 mL	10 units
1.0 mL	10 mg/mL	2.5 mg	0.25 mL	25 units
1.0 mL	10 mg/mL	5 mg	0.50 mL	50 units

5-Amino-1MQ Reconstitution Guide

BAC water added	Final concentration	Research amount	Draw volume	U-100 syringe units
2.0 mL	10 mg/mL	1 mg	0.10 mL	10 units
2.0 mL	10 mg/mL	2.5 mg	0.25 mL	25 units
2.0 mL	10 mg/mL	5 mg	0.50 mL	50 units

5-Amino-1MQ Reconstitution Guide

BAC water added	Final concentration	Research amount	Draw volume	U-100 syringe units
3.0 mL	16.7 mg/mL	1 mg	0.06 mL	6 units
3.0 mL	16.7 mg/mL	2.5 mg	0.15 mL	15 units
3.0 mL	16.7 mg/mL	5 mg	0.30 mL	30 units
3.0 mL	16.7 mg/mL	10 mg	0.60 mL	60 units

5-Amino-1MQ vs AOD-9604 vs Semaglutide vs NAD+

Compound	Mechanism	Route	Acts on appetite?	FDA status
5-Amino-1MQ	NNMT inhibitor; raises NAD+, shrinks fat cells	Oral capsule (50–150 mg/day)	No	Not FDA-approved
AOD-9604	Modified GH fragment; promotes fat oxidation	Subcutaneous injection	No	Not FDA-approved
Semaglutide	GLP-1 receptor agonist; suppresses appetite	Subcutaneous injection or oral	Yes (strong)	FDA-approved (T2D and obesity)
NAD+ (intravenous or subcutaneous)	Direct NAD+ supplementation	IV infusion or subcutaneous	No	Not FDA-approved as a drug

Where the 8–12 week cycle comes from

Cycle length	Evidence level	Best interpretation
About 2 weeks	Close to the 11-day mouse proof-of-concept study	A short animal-study reference point, not a human minimum cycle.
4 weeks	Matches the 28-day mouse study duration	A published animal duration, not a validated human cycle.
6–8 weeks	Near the longest multi-week mouse exposure highlighted here	Closer to published animal-study duration, but still not human cycle evidence.
8–12 weeks	Community-reported convention	Common online cycle structure with no completed human trial establishing it.
Longer than 12 weeks	Human long-term data are lacking	Evidence becomes even thinner as duration extends beyond the common community range.

Cycle Length Is Not the Same as Half-Life

Concept	What it means	What it does not mean
Half-life	How fast measured drug concentration declines in a specific PK study	How many weeks a cycle should last
Dose interval	How often a study administers a compound	How long the full experiment should continue
Cycle length	Total exposure period in a study or community schedule	A value that can be calculated from half-life alone
Washout	Time after exposure stops	A proven 4–6 week requirement for 5-Amino-1MQ

Storage and handling

The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.

Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
Cloudy solution, with particles or a color change: discard. There is no recovery.

Lab tests and monitoring

This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.

Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.

Evidence limits

What these numbers are and what they are not. The values above were preserved exactly as they appear in the source, without reinterpretation. What the source describes as community practice is marked as such in the tables; what came from a published trial is too. A dose repeated by many people does not become a validated dose by repetition.

Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.

← Back to all compounds